One of the most investigated and therapeutically targeted oncogenes in prostate cancer is the androgen receptor (AR), which is frequently amplified and/or mutated in metastatic diseases whereby mediates the androgen-dependent transcription of growth-related genes toward prostate tumorigenesis [13, 14]. Here, AR is linked to metastatic neoplasm.